As the SARS-CoV-2 virus shares relatively large protein sequences homologous to grass pollens,dust mites,and molds,our objective was to assess the potential overlap between the COVID-19mRNA vaccines fromPfizer-BioNtec...As the SARS-CoV-2 virus shares relatively large protein sequences homologous to grass pollens,dust mites,and molds,our objective was to assess the potential overlap between the COVID-19mRNA vaccines fromPfizer-BioNtech andModerna and known allergens.We found 7 common allergens with potential for cross-reactivity with the Pfizer vaccine and 19 with theModerna vaccine,including common grasses,molds,and dust mites.T-cell mediated antigen cross-reactivity between viruses and allergens is a relatively new area of study in clinical immunology;a discipline that may be particularly useful regarding the SARS-CoV-2 virus and the allergic response in humans.These results suggest that vaccination with the Pfizer-BioNtech andModerna COVID-19 vaccinesmay contribute to T-cell cross-reactivity with allergens that impact allergic asthma and allergic rhinitis.Further research should assess the clinical implications of COVID-19 vaccination on the severity and symptomatology of the allergic disease,in addition to natural viral infection.展开更多
文摘As the SARS-CoV-2 virus shares relatively large protein sequences homologous to grass pollens,dust mites,and molds,our objective was to assess the potential overlap between the COVID-19mRNA vaccines fromPfizer-BioNtech andModerna and known allergens.We found 7 common allergens with potential for cross-reactivity with the Pfizer vaccine and 19 with theModerna vaccine,including common grasses,molds,and dust mites.T-cell mediated antigen cross-reactivity between viruses and allergens is a relatively new area of study in clinical immunology;a discipline that may be particularly useful regarding the SARS-CoV-2 virus and the allergic response in humans.These results suggest that vaccination with the Pfizer-BioNtech andModerna COVID-19 vaccinesmay contribute to T-cell cross-reactivity with allergens that impact allergic asthma and allergic rhinitis.Further research should assess the clinical implications of COVID-19 vaccination on the severity and symptomatology of the allergic disease,in addition to natural viral infection.
